In our patient, the decision to initiate a pazopanib trial was based on previous studies that established a correlation between increased tumor vascularity and intratumoral hemorrhage (which was observed in our patient), with elevated levels of VEGF expression and tyrosine kinase activity (22, 46, 77). This evidence concerns the gene VEGFA and neoplasm.